SPI Healthcare
3.597,97
PKT
+5,14
PKT
+0,14
%
Werbung
Leider sind zu diesem Wert keine aktuellen Kursdaten verfügbar, die Stammdaten finden Sie im unteren Seitenbereich.
Analysen zu SPI Healthcare-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 24.10.12 | Novartis underperform | Cheuvreux SA | |
| 24.10.12 | Novartis buy | Société Générale Group S.A. (SG) | |
| 24.10.12 | Sonova buy | Vontobel Research | |
| 23.10.12 | Novartis buy | Nomura | |
| 22.10.12 | Sonova neutral | Sarasin Research | |
| 19.10.12 | Novartis outperform | Exane-BNP Paribas SA | |
| 18.10.12 | Straumann hold | Vontobel Research | |
| 17.10.12 | Novartis reduce | Vontobel Research | |
| 17.10.12 | Novartis outperform | Exane-BNP Paribas SA | |
| 16.10.12 | Novartis neutral | Citigroup Corp. | |
| 16.10.12 | Novartis underperform | Banc of America Securities-Merrill Lynch | |
| 16.10.12 | Novartis outperform | Credit Suisse Group | |
| 12.10.12 | Novartis outperform | Credit Suisse Group | |
| 12.10.12 | Novartis buy | Nomura | |
| 12.10.12 | Novartis reduce | Vontobel Research | |
| 12.10.12 | Novartis buy | UBS AG | |
| 11.10.12 | Novartis buy | Deutsche Bank AG | |
| 11.10.12 | Novartis buy | UBS AG | |
| 10.10.12 | Sonova underperform | Exane-BNP Paribas SA | |
| 08.10.12 | Novartis halten | Independent Research GmbH | |
| 08.10.12 | Novartis reduce | Vontobel Research | |
| 05.10.12 | Lonza hold | Vontobel Research | |
| 05.10.12 | Sonova neutral | Sarasin Research | |
| 05.10.12 | Straumann hold | Vontobel Research | |
| 05.10.12 | Sonova buy | Vontobel Research | |
| 04.10.12 | Novartis buy | Nomura | |
| 02.10.12 | Tecan (N) neutral | Sarasin Research | |
| 01.10.12 | Novartis buy | Sarasin Research | |
| 01.10.12 | Novartis reduce | Vontobel Research | |
| 27.09.12 | Sonova neutral | Sarasin Research | |
| 27.09.12 | Sonova underperform | Exane-BNP Paribas SA | |
| 24.09.12 | Novartis reduce | Vontobel Research | |
| 24.09.12 | Novartis buy | Sarasin Research | |
| 14.09.12 | Lonza neutral | J.P. Morgan Cazenove | |
| 13.09.12 | Novartis reduce | Vontobel Research | |
| 12.09.12 | Novartis neutral | J.P. Morgan Cazenove | |
| 11.09.12 | Newron PharmaceuticalsAz. buy | Vontobel Research | |
| 11.09.12 | Novartis underperform | Banc of America Securities-Merrill Lynch | |
| 11.09.12 | Novartis outperform | Sanford C. Bernstein and Co., Inc. | |
| 10.09.12 | Newron PharmaceuticalsAz. buy | Vontobel Research |